DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations in the Asia pacific pharmaceutical markets (Australia, Hong Kong, Indonesia,…
MARKET OUTLOOK The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population,…
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL,…
The treatment journey for multiple sclerosis (MS) patients in Europe is complicated and individualized, driven by the availability of a broad array of disease-modifying therapies (DMTs)—…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the prevalence of the disease. The body of…
Market Outlook: Squamous cell carcinoma of the head and neck (SCCHN) is an anatomically and biologically heterogeneous disease that has historically proven to be a complex challenge for drug…
Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a…
Heart failure (HF) can be categorized into acute or chronic, and we focus on both settings in this report. HF patients are subject to high rates of mortality and morbidity. While much progress…
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment has been dominated by…
The high number of premium-priced NSCLC therapies and the large number of NSCLC patients result in significant financial burden for payers. These costs are set to increase with the approval of…
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of NHL treatment, and recent…
Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, but the high costs associated with these agents present significant challenges for payers. The…
Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, but the high costs associated with these agents present significant challenges for payers. The…
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of NHL treatment, and recent…
Attention-deficit-hyperactivity disorder (ADHD) affects over 40 million people—children, adolescents, and adults—across the major pharmaceutical markets. The key treatment goals for both…
